InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

Current share price for DXB : $0.275 0.015 (5.17%)+

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$165 Application for quotation of securities - DXB 6 Mar 2025 1:21PM $0.440 $0.275 fallen by 37.50%
$165 Dimerix receives initial upfront payment from FUSO 4 Mar 2025 8:33AM $0.440 $0.275 fallen by 37.50%
$165 Application for quotation of securities - DXB 3 Mar 2025 3:08PM $0.443 $0.275 fallen by 37.85%
$165 Investor Presentation 26 Feb 2025 9:31AM $0.485 $0.275 fallen by 43.30%
$165 Half-Year Financial Report & Appendix 4D - 31 December 2024 25 Feb 2025 9:07AM $0.515 $0.275 fallen by 46.60%
$165 Application for quotation of securities - DXB 21 Feb 2025 3:14PM $0.488 $0.275 fallen by 43.59%
$165 Application for quotation of securities - DXB 18 Feb 2025 1:56PM $0.493 $0.275 fallen by 44.16%
$165 Application for quotation of securities - DXB 12 Feb 2025 1:24PM $0.520 $0.275 fallen by 47.12%
$165 Application for quotation of securities - DXB 10 Feb 2025 4:53PM $0.460 $0.275 fallen by 40.22%
$165 Application for quotation of securities - DXB 5 Feb 2025 2:32PM $0.465 $0.275 fallen by 40.86%
$165 Appendix 3Y Correction 5 Feb 2025 8:37AM $0.480 $0.275 fallen by 42.71%
$165 Change of Director's Interest Notice - NW 4 Feb 2025 2:53PM $0.465 $0.275 fallen by 40.86%
$165 Investor Presentation - Euroz Hartley Healthcare Forum 4 Feb 2025 9:04AM $0.435 $0.275 fallen by 36.78%
$165 Application for quotation of securities - DXB 31 Jan 2025 1:59PM $0.453 $0.275 fallen by 39.23%
$165 Quarterly Appendix 4C and Activities Report 28 Jan 2025 8:33AM $0.445 $0.275 fallen by 38.20%
$165 Application for quotation of securities - DXB 24 Jan 2025 3:28PM $0.450 $0.275 fallen by 38.89%
$165 Application for quotation of securities - DXB 22 Jan 2025 1:13PM $0.465 $0.275 fallen by 40.86%
$165 Application for quotation of securities - DXB 16 Jan 2025 10:20AM $0.525 $0.275 fallen by 47.62%
$165 First Paediatric Patient Recruited for ACTION3 16 Jan 2025 8:24AM $0.520 $0.275 fallen by 47.12%
$165 Application for quotation of securities - DXB 13 Jan 2025 1:05PM $0.495 $0.275 fallen by 44.44%
$165 Investor Presentation 7 Jan 2025 9:11AM $0.355 $0.275 fallen by 22.54%
$165 Dimerix enters Development and License Agreement for Japan 7 Jan 2025 8:22AM $0.355 $0.275 fallen by 22.54%
$165 DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment Complete 30 Dec 2024 8:25AM $0.330 $0.275 fallen by 16.67%
$165 Application for quotation of securities - DXB 16 Dec 2024 2:27PM $0.340 $0.275 fallen by 19.12%
$165 Successful planned IDMC review of ACTION3 trial 20 Nov 2024 9:10AM $0.345 $0.275 fallen by 20.29%

101 - 125 of 723 results

Page 5 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.